These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11579964)

  • 1. Lupus anticoagulant in myasthenia gravis associated with IgM gammopathy.
    Ishikawa S; Komiyama Y; Kobayashi H; Tsuyuzaki J; Tokunaga S; Miyazaki A; Hanyu N; Ikeda S
    Intern Med; 2001 Sep; 40(9):952-5. PubMed ID: 11579964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.
    Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A
    Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström's macroglobulinemia and myasthenia gravis.
    Bartoloni C; Scoppetta C; Flamini G; Guidi L; Bartoccioni E; Lambiase M; Gambassi G; Terranova T
    J Clin Lab Immunol; 1981 Nov; 6(3):275-8. PubMed ID: 6802976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM monoclonal gammopathy, lymphoid proliferations and lupus anticoagulant.
    Disdier P; Swiader L; Aillaud MF; Boucraut J; Harlé JR; Weiller PJ
    Am J Med; 1997 Mar; 102(3):319-20. PubMed ID: 9217609
    [No Abstract]   [Full Text] [Related]  

  • 5. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of myasthenia gravis with dropped head: a report of 2 cases and review of the literature.
    Tamai M; Hashimoto T; Isobe T; Sato H; Doden T; Nakano T
    Neuromuscul Disord; 2015 May; 25(5):429-31. PubMed ID: 25747003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevalence of prolonged APTT and lupus anticoagulant in autoimmune thyroid disease].
    Tani Y; Morita M; Noguchi S
    Rinsho Byori; 1997 Sep; 45(9):899-902. PubMed ID: 9311265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.
    Guptill JT; Juel VC; Massey JM; Anderson AC; Chopra M; Yi JS; Esfandiari E; Buchanan T; Smith B; Atherfold P; Jones E; Howard JF
    Autoimmunity; 2016 Nov; 49(7):472-479. PubMed ID: 27684107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmapheresis does not affect polysomnographic parameters in patients with myasthenia gravis: a case series study.
    Yeh JH; Chen WH; Chiu HC; Lee CT; Hsu CY
    Artif Organs; 2010 Jun; 34(6):E200-3. PubMed ID: 20456321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis: options and timing of immunomodulatory treatment.
    Spring PJ; Spies JM
    BioDrugs; 2001; 15(3):173-83. PubMed ID: 11437683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double filtration plasmapheresis in myasthenia gravis--analysis of clinical efficacy and prognostic parameters.
    Yeh JH; Chiu HC
    Acta Neurol Scand; 1999 Nov; 100(5):305-9. PubMed ID: 10536917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
    Pták J
    Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to plasmapheresis in myasthenia gravis patients: 22 cases report.
    Yazdi MF; Baghianimoghadam M; Nazmiyeh H; Ahmadabadi AD; Adabi MA
    Rom J Intern Med; 2012; 50(3):245-7. PubMed ID: 23330293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis.
    Nagayasu T; Yamayoshi T; Matsumoto K; Ide N; Hashizume S; Nomura M; Muraoka M; Tagawa T; Akamine S; Oka T
    Jpn J Thorac Cardiovasc Surg; 2005 Jan; 53(1):2-7. PubMed ID: 15724495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM.
    Yamamoto T; Vincent A; Ciulla TA; Lang B; Johnston I; Newsom-Davis J
    Ann Neurol; 1991 Oct; 30(4):550-7. PubMed ID: 1665051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient.
    Renard D; Candon S; Jacob M; Trusson R; Reboul P
    Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.
    Yeh JH; Chiu HC
    Acta Neurol Scand; 1999 Mar; 99(3):147-51. PubMed ID: 10100957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of double filtration plasmapheresis on nocturnal respiratory function in myasthenic patients.
    Yeh JH; Lin CM; Chen WH; Chiu HC
    Artif Organs; 2013 Dec; 37(12):1076-9. PubMed ID: 23865547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.